Matthew A. Hulverson

Matthew A. Hulverson

Auto-generated profile, based on publicly available information

Matthew A. Hulverson

Department of Medicine, Division of Allergy and Infectious Diseases, Center for Emerging and Reemerging Infectious Diseases (CERID), University of Washington

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 February 2025 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Open access
RSRoberto Sánchez Sánchez Sánchez
Roberto Sánchez Sánchez Sánchez
AHAna Huertas-López
Ana Huertas-López
ATAndrea Largo-De la Torre
Andrea Largo-De la Torre
IFIgnacio Ferre
Ignacio Ferre
FDFilippo Maria Dini
Filippo Maria Dini
LOLuis Miguel Ortega-Mora
Luis Miguel Ortega-Mora
Drug development for congenital toxoplasmosis is challenging since first-line therapy has a high rate of adverse effects and exhibits suboptimal efficacy. Bumped kinase inhibitors (BKIs), targeting protein kinases with small gatekeeper residues, have been found to be effective against Toxoplasma gondii . The efficacy of BKI-1748 administered later than 2 days post-infection (p.i.), a scenario that may better reflect its real-world use as a therapeutic candidate, has not been investigated in T. gondii -infected pregnant sheep. For this purpose, 19 pregnant sheep were assigned to three experimental groups. Group 1 (G1, n = 8) and group 2 (G2, n = 8) were dosed orally with 10 TgShSp1 sporulated oocysts at 90 days of gestation (dg). Animals from group 3 (G3, n = 3) were simultaneously mock dosed with phosphate-buffered solution (PBS). In G1, BKI-1748 was administered orally from day 7 p.i. (fever and increased serum IFNγ levels) onward, maintaining drug exposure for 20 days (10 doses at 15 mg/kg every 2 days). Treated animals (G1) exhibited significantly lower rectal temperatures (on days 8 and 9 p.i.), serum IFNγ levels (on day 10 p.i.), and specific IgG levels when compared with non-treated animals (G2). At delivery, significantly higher percentages of healthy lambs were found in infected/treated sheep in G1 (73.3%) and in uninfected sheep in G3 (80%) compared with infected/untreated sheep in G2 (31.3%). Concerning congenital transmission, parasite DNA was neither detected in placenta nor target tissues (brain and lungs) from the fetuses/lambs in G1(infected/treated) and G3 (uninfected). By contrast, parasite DNA was detected in all placentas and lambs from G2 (infected/untreated), except for one sheep that aborted on day 13 p.i.

23 May 2025 in ACS Infectious Diseases
Verified
Journal Article
Open access
JMJemma A. Montgomery
Jemma A. Montgomery
PAP. Holland Alday
P. Holland Alday
RCRyan Choi
Ryan Choi
MKMonique Khim
Monique Khim
BSBart L. Staker
Bart L. Staker
JDJ. Stone Doggett
J. Stone Doggett
A subset of bumped kinase inhibitors (BKIs) has been optimized to inhibit the calcium dependent protein kinase 1 (TgCDPK1; TGGT1_301440) of Toxoplasma gondii and pathogenic Cryptosporidium species. Extensive preclinical development of BKIs has identified BKI-1748 as a highly effective lead compound for toxoplasmosis. Phenotypic and therapeutic effects of BKIs have suggested that BKIs may have targets other than TgCDPK1. The mechanism of BKI-1748 action was further investigated using a forward genetic screen of chemical mutagenesis, selection of BKI-1748 resistant clones, and whole genome sequence analysis. Resistant clones were found to have single nucleotide changes in the ATP binding site of the T. gondii mitogen-activated protein kinase-like 1 gene (TgMAPKL1; TGGT1_312570). One of the mutations found in the ATP binding pocket, Leu162Gln, was introduced into a wild-type strain, resulting in 2 to 6-fold resistance to BKI-1748 and a set of structurally varied BKIs. A strain with a TgCDPK1 gatekeeper substitution, Gly128Met, was also created and demonstrated a similar degree of resistance. The combination of TgMAPKL1 and TgCDPK1 substitutions together in a single strain resulted in a substantial increase in resistance to BKIs, up to 157-fold. The identification of TgMAPKL1 in addition to TgCDPK1 as a target of BKIs provides a greater understanding of the BKI mechanism of action that is important for further therapeutic development and suggests a high genetic barrier to meaningful drug resistance for this promising class of compounds.

10 February 2021 in ACS Infectious Diseases
Verified
Journal Article
Closed access
MHMatthew A. Hulverson
Matthew A. Hulverson
RCRyan Choi
Ryan Choi
RVRama S. R. Vidadala
Rama S. R. Vidadala
GWGrant R. Whitman
Grant R. Whitman
VVVenkata Narayana Vidadala
Venkata Narayana Vidadala
WVWesley C. Van Voorhis
Wesley C. Van Voorhis

20 March 2024 in Molecular Cancer Therapeutics
Verified
Journal Article
Closed access
PDF file
TUTakuma Uo
Takuma Uo
KOKayode K. Ojo
Kayode K. Ojo
CSCynthia C. T. Sprenger
Cynthia C. T. Sprenger
KEKathryn Soriano Epilepsia
Kathryn Soriano Epilepsia
BPB. Gayani K. Perera
B. Gayani K. Perera
SPStephen Plymate
Stephen Plymate
Metastatic castration-resistant prostate cancer remains incurable regardless of recent therapeutic advances. Prostate cancer tumors display highly glycolytic phenotypes as the cancer progresses. Nonspecific inhibitors of glycolysis have not been utilized successfully for chemotherapy, because of their penchant to cause systemic toxicity. This study reports the preclinical activity, safety, and pharmacokinetics of a novel small-molecule preclinical candidate, BKIDC-1553, with antiglycolytic activity. We tested a large battery of prostate cancer cell lines for inhibition of cell proliferation, in vitro. Cell-cycle, metabolic, and enzymatic assays were used to demonstrate their mechanism of action. A human patient-derived xenograft model implanted in mice and a human organoid were studied for sensitivity to our BKIDC preclinical candidate. A battery of pharmacokinetic experiments, absorption, distribution, metabolism, and excretion experiments, and in vitro and in vivo toxicology experiments were carried out to assess readiness for clinical trials. We demonstrate a new class of small-molecule inhibitors where antiglycolytic activity in prostate cancer cell lines is mediated through inhibition of hexokinase 2. These compounds display selective growth inhibition across multiple prostate cancer models. We describe a lead BKIDC-1553 that demonstrates promising activity in a preclinical xenograft model of advanced prostate cancer, equivalent to that of enzalutamide. BKIDC-1553 demonstrates safety and pharmacologic properties consistent with a compound that can be taken into human studies with expectations of a good safety margin and predicted dosing for efficacy. This work supports testing BKIDC-1553 and its derivatives in clinical trials for patients with advanced prostate cancer.

5 June 2023 in Journal of Natural Products
Verified
Journal Article
Closed access
JLJin Woo Lee
Jin Woo Lee
JCJennifer Collins
Jennifer Collins
MHMatthew A. Hulverson
Matthew A. Hulverson
LALaarni Kendra T. Aguila
Laarni Kendra T. Aguila
CKCaroline M. Kim
Caroline M. Kim
RCRobert Cichewicz
Robert Cichewicz

19 March 2021 in ACS Infectious Diseases
Verified
Journal Article
Closed access
MHMatthew A. Hulverson
Matthew A. Hulverson
RCRyan Choi
Ryan Choi
MMMolly McCloskey
Molly McCloskey
GWGrant R. Whitman
Grant R. Whitman
KOKayode K. Ojo
Kayode K. Ojo
WVWesley C. Van Voorhis
Wesley C. Van Voorhis